FILING ANALYSIS · THURSDAY, OCTOBER 22
PAVmed Inc. PAVM — 8-K: Entry into a Material Definitive Agreement
negative
PAVmed's subsidiary Lucid Diagnostics has raised $15 million through the sale of 15,000 shares of Series C Convertible Preferred Stock, which may lead to dilution for existing shareholders.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →